Form Type: 4

SEC EDGAR Link
Accession Number:0000899243-20-002037
Date:2020-01-23
Issuer: FULCRUM THERAPEUTICS, INC. (FULC)
Original Submission Date:

Reporting Person:

THOMSON PETER G.
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET CAMBRIDGE, MA 02139

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-01-23 S 4,738 d $17.17 33,833 direct
COMMON STOCK 2020-01-23 S 262 d $18.05 33,571 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 16.87 2020-01-23 deemed execution date A 33,100 (a) 2030-01-22 common stock 33,100 $16.87 33,100 direct
Footnotes
IDfootnote
f1 the sales reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on december 9, 2019.
f2 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $16.78 to $17.73, inclusive. the reporting person undertakes to provide to fulcrum therapeutics, inc., any security holder of fulcrum therapeutics, inc. or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this form 4.
f3 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $17.98 to $18.26, inclusive. the reporting person undertakes to provide to fulcrum therapeutics, inc., any security holder of fulcrum therapeutics, inc. or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this form 4.
f4 this option was granted on january 23, 2020 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of january 1, 2020, subject to continued service.
WhaleWisdom Logo

Elevate your investments